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The association between a smaller retinal arteriolar-to-
venular ratio (AVR) and incident diabetes may be due to
arteriolar narrowing, venular dilatation, or both. We inves-
tigated associations between baseline vessel diameters and
incident impaired fasting glucose or diabetes in a popula-
tion-based cohort (aged>55 years). Baseline retinal vessel
diameters (1990–1993) were measured on digitized images
of 2,309 subjects with a normal glucose tolerance test
(postload glucose <7.8 mmol/l). At follow-up (1997–1999),
impaired fasting glucose was defined as 6.1–7.0 mmol/l and
diabetes as >7.0 mmol/l and/or antidiabetic medication
use. Odds ratios (ORs) per SD increase in venular diame-
ters were 1.13 (95% CI 1.00–1.29) for impaired fasting
glucose and 1.09 (0.90–1.33) for diabetes. ORs per SD
decrease in arteriolar diameters were 1.12 (0.98–1.27) and
1.08 (0.89–1.31) and per SD decrease in AVR were 1.29
(1.13–1.46) and 1.19 (0.98–1.45). After adjustment for
cardiovascular risk factors, the associations were unal-
tered for venules and disappeared for arterioles. After
stratification on age, associations between venular dilata-
tion and impaired fasting glucose (1.23 [1.02–1.47]) or
diabetes (1.18 [0.89–1.56]) were mainly present in partic-
ipants aged <70 years. In conclusion, in our study, the risk
of impaired fasting glucose and diabetes with AVR was
explained by venular dilatation rather than arteriolar nar-
rowing, warranting more focus on the causes of this dila-
tation. Diabetes 55:506–510, 2006
Epidemiological studies have shown that highBMI, parental history of diabetes, and impairedglucose tolerance are some of the factors in-volved in the development of diabetes (1,2).
Microvascular changes such as impaired reactivity and
disturbed blood flow in microvessels have also been
hypothesized to contribute to the pathogenesis of diabetes
(3,4). Several cross-sectional studies have shown these
abnormalities not only in people with diabetes (3) but also
in those at high risk of developing diabetes, including
people with impaired glucose tolerance or first-degree
relatives of diabetic patients (4).
Until recently, prospective population-based data re-
garding the role of microvascular abnormalities in diabe-
tes were lacking due to difficulties in noninvasively
assessing the microcirculation in vivo. A semiautomated
system was developed to measure retinal vessel diameters
(5). It was suggested that the retinal arteriolar-to-venular
ratio (AVR) thus obtained was a marker of generalized
arteriolar narrowing and that a smaller AVR was related to
incident diabetes (6). Due to the nature of ratio measures
like this one, it is difficult to judge whether this relation is
due to arteriolar narrowing or venular dilatation. Studying
the arteriolar and venular diameters separately may be
important for elucidating the microvascular complications
of diabetes, such as retinal venular dilatation that has been
reported to be present already in the pre-diabetic stage of
hyperglycemia (7–9).
Therefore, we investigated in the population-based Rot-
terdam Study whether the AVR was associated with an
increased risk of impaired fasting glucose or diabetes and
whether this was explained by retinal arteriolar narrow-
ing, venular dilatation, or both.
RESEARCH DESIGN AND METHODS
The present study was performed as part of the Rotterdam Study, a prospec-
tive population-based cohort study (10). A total of 7,983 inhabitants of a
district of Rotterdam, aged 55 years, agreed to participate in the study
(response rate of 78%). Because the ophthalmic part became operational after
the screening of randomly invited participants had already started, a smaller
number (n  6,780) underwent the ophthalmic examination (11). The study
was conducted according to the tenets of the Declaration of Helsinki, and the
appropriate medical ethics committees approved the protocol. Written in-
formed consent was obtained from all participants. Baseline interviews and
examinations took place from 1990 to mid-1993, and the follow-up screening
occurred between 1997 and 1999.
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Retinal vessel diameter measurements at baseline. Retinal vessel diam-
eters were measured on fundus color transparencies. These transparencies,
covering a 20° field centered on the optic disc, were digitized with a
high-resolution scanner (Nikon LS-4000; Nikon, Tokyo, Japan) (12). For each
person, the image of one eye with the best quality was chosen and analyzed
with a semiautomated system (Retinal Analysis; Optimate, Madison, WI)
(Department of Ophthalmology & Visual Science, University of Wisconsin-
Madison, Madison, WI) by four trained graders masked for the end points (11).
We used the improved Parr-Hubbard-Knudtson formula to compute the
summary vessel measures (13) and additionally adjusted for the differences in
magnification in case of refractive errors of the eye (14). Sum values were
calculated for the arteriolar and venular blood column diameters (in m), the
AVR being the ratio of these. In a random sample of 100 participants, we found
no differences between right and left eyes for the arteriolar and venular
diameters.
Ascertainment of incident cases of impaired fasting glucose and diabe-
tes. At baseline, a nonfasting blood sample was drawn followed by a 75-g oral
glucose tolerance test in participants who were not on antidiabetic medication
(15). Two hours later, a second blood sample was obtained. Glucose levels
were measured by the glucose hexokinase method (15).
At the follow-up examination, the oral glucose tolerance test was not
performed; instead, blood samples were drawn at the research center after
overnight fasting (8–14 h). Definitions for incident cases of impaired fasting
glucose and diabetes were adapted from the American Diabetes Association
guidelines (16,17). For the current study, only subjects who had a normal oral
glucose tolerance test (postload glucose value 7.8 mmol/l) and did not use
antidiabetic medication at baseline were included. Incident impaired fasting
glucose was defined as having a fasting glucose value of 6.1–7.0 mmol/l and
incident diabetes as fasting blood glucose value 7.0 mmol/l. Also, subjects
who started using antidiabetic medication during follow-up were classified as
having incident diabetes.
Assessment of confounders. Blood pressure was measured in sitting
position at the right brachial artery with a random-zero sphygmomanometer.
In the analyses, we used the average of two measurements taken at one
occasion. Information on smoking habits was derived from the baseline
interview. Smoking was categorized as never, former, or current. BMI was
computed as weight (in kilograms) divided by the square of height (in meters)
(kg/m2). Nonfasting serum total cholesterol and HDL was determined by an
enzymatic procedure (18). Serum levels of C-reactive protein were determined
by the rate near infrared particle immunoassay method (Immage high sensi-
tive C-reactive protein; Beckman Coulter). Atherosclerotic plaques, assessed
by ultrasound at the bifurcation, common, and internal carotid artery on both
sides, were defined as focal thickening of the vessel wall (of at least 1.5 times
the average intima-media thickness) relative to adjacent segments with or
without calcified components. The carotid plaque score (range 0–6) reflected
the number of these locations with plaques (19).
Study sample. Of 6,780 participants in the ophthalmic part of the baseline
study, 5,674 had gradable fundus transparencies for retinal vessel measure-
ments. Data on glucose tolerance test and antidiabetic medication were
available for 4,972 individuals. Of these, 3,699 participants had a normal
glucose tolerance test and did not use antidiabetic medication at baseline and
thus formed the cohort at risk for impaired fasting glucose or diabetes. During
follow-up, 443 participants died and 947 refused or were unable to participate
at the follow-up examination, leaving 2,309 participants for the current
analyses (Figure 1).
Statistical analysis. ANCOVA was used to compare baseline characteristics
of participants to nonparticipants at follow-up. Arteriolar and venular diam-
eters and AVR were analyzed both in quartiles and linearly (per SD difference)
with logistic regression models. Odds ratios (ORs) and 95% CIs were calcu-
lated for incident impaired fasting glucose and diabetes. Participants who
developed impaired fasting glucose during follow-up were excluded from
analyses where diabetes was the outcome, and vice versa. For additional
adjustments we included cardiovascular risk factors that we previously
showed to be associated with retinal vessel diameters (11) and that also have
been implicated in the pathogenesis of diabetes. We adjusted for age, sex,
follow-up time, and additionally for other cardiovascular risk factors. We
repeated the analyses after stratifying on age. The cutoff value of 70 years was
chosen to secure enough cases in both strata. All analyses were performed
with SPSS Windows version 11.0 (SPSS, Chicago, IL).
RESULTS
Table 1 shows that nonparticipants were on average older,
more often women and smokers, and had higher blood
pressures and more plaques in the carotid arteries. People
who died during follow-up had a worse cardiovascular risk
profile compared with participants. After a mean follow-up
time of 6.4 years (range 5.2–9.5), 305 participants devel-
oped impaired fasting glucose and 118 developed diabetes.
In people who developed impaired fasting glucose, the
mean arteriolar diameter at baseline was 146.3  13.5 m,
venular diameter 224.8  20.6 m, and AVR 0.65  0.05,
whereas in those who developed diabetes these values
were 146.4  13.5, 224.1  19.8, and 0.66  0.06 m,
respectively. In the remaining participants the mean arte-
riolar diameter was 147.9 14.2, venular diameter 222.4
19.7, and AVR 0.67  0.06 m.
The lowest quartile of arteriolar diameters compared
with the highest one was neither related to an increased
risk of impaired fasting glucose nor to the risk of diabetes
(Table 2). However, comparing the highest quartile of
venular diameters to the lowest one showed a 46% in-
creased risk of impaired fasting glucose. There was no
consistent trend between quartiles of venular diameters
FIG. 1. Flowchart of the study population.
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and the risk of diabetes. Finally, the lowest quartile of AVR
compared with the highest one gave a significantly in-
creased risk of 93% for impaired fasting glucose and of 80%
for diabetes.
Table 3 shows that each SD decrease in arteriolar
diameters increased the risk of impaired fasting glucose by
12%, whereas 1 SD increase in venular diameters resulted
in a 13% increased risk. The corresponding nonsignificant
increases in risk for diabetes were 8 and 9%. A decrease in
the resulting AVR at baseline was associated with signifi-
cantly increased risk of impaired fasting glucose and
borderline significantly with diabetes. For each SD de-
crease in AVR, the risk of impaired fasting glucose in-
creased by 29% and of diabetes by 19%.
Table 4 shows that after adjusting for other known
cardiovascular risk factors, the associations of smaller
arteriolar diameters with impaired fasting glucose and
diabetes completely disappeared. The strength of the
association between larger venular diameters and im-
paired fasting glucose remained the same, albeit border-
line significant. Even for diabetes the nonsignificant OR
remained the same.
Stratification on age revealed that the associations of
larger venular diameters with impaired fasting glucose or
diabetes were stronger in younger and absent in the older
participants (Table 5).
DISCUSSION
Our data provide evidence that retinal venular dilatation
rather than arteriolar narrowing explains the associations
between smaller AVR and impaired fasting glucose or
diabetes. The associations with venular dilatation were
more pronounced in the younger participants.
It has been suggested that venular dilatation is one of








n 2,309 947 443
Age (years) 65.0 6.5 68.7 8.1 3.7 (3.1–4.2)# 74.4 8.4 9.4 (8.7–10.1)#
Sex (% female) 57.0 62.0 4.4 (0.6–8.2)# 47.0 12.3 (17.7 to6.8)#
Systolic blood pressure
(mmHg) 133.7 20.0 139.4 22.9 3.2 (1.6–4.8)# 143.8 23.5 3.3 (1.0–5.6)#
Diastolic blood pressure
(mmHg) 73.3 10.8 74.2 11.4 1.3 (0.4–2.2)# 73.6 12.3 1.1 (0.2 to 2.3)
Current smoking (%) 21.8 28.2 10.2 (7.0–13.5)# 27.9 13.9 (9.2–18.6)#
BMI (kg/m2) 26.2 3.4 26.3 3.7 0.0 (0.3 to 0.3) 25.8 3.7 0.6 (0.9 to0.2)#
Total serum cholesterol
(mmol/l) 6.66 1.16 6.68 1.17 0.02 (0.07 to 0.11) 6.30 1.28 0.22 (0.34 to0.09)#
Serum HDL cholesterol
(mmol/l) 1.38 0.35 1.39 0.36 0.01 (0.02 to 0.03) 1.31 0.36 0.03 (0.06 to 0.01)
C-reactive protein (mg/l) 2.42 2.74 0.33 (0.06 to 0.72) 5.01 2.44 (1.88–3.00)#
Number of carotid artery
plaques 4 (%) 11.0 17.1 3.9 (1.0–6.8)# 24.0 5.6 (1.5–9.8)#
Retinal AVR 0.67 0.06 0.66 0.06 0.002 (0.006 to 0.003) 0.66 0.06 0.009 (0.016 to0.003)#
Retinal arteriolar
diameter (m) 147.7 14.1 146.4 14.4 0.4 (1.5 to 0.7) 145.0 15.0 0.5 (2.1 to 1.1)
Retinal venular diameter
(m) 222.8 19.9 220.9 20.8 0.1 (1.5 to 1.6) 221.1 20.5 2.5 (0.3–4.7)#
Data are unadjusted means  SD or %. *Unable or refused at follow-up. †Age and sex adjusted if applicable. ‡Nonparticipants versus
participants. §Subjects who died before the follow-up examination. Deceased subjects versus participants. #Significant (P  0.05).
TABLE 2
ORs of incident impaired fasting glucose or incident diabetes per








4. (156.4–204.7) 1.0 (reference) 1.0 (reference)
3. (147.1–156.3) 1.04 (0.73–1.49) 1.42 (0.82–2.46)
2. (137.8–147.0) 1.29 (0.92–1.82) 1.58 (0.92–2.72)
1. (95.0–137.7) 1.17 (0.82–1.66) 1.29 (0.73–2.28)
Venular diameter (m)
1. (135.1–209.0) 1.0 (reference) 1.0 (reference)
2. (208.9–222.1) 1.33 (0.94–1.90) 1.24 (0.73–2.12)
3. (222.0–235.4) 1.20 (0.84–1.72) 0.91 (0.52–1.62)
4. (235.3–313.6) 1.46 (1.02–2.08) 1.41 (0.83–2.38)
AVR
4. (0.70–0.87) 1.0 (reference) 1.0 (reference)
3. (0.66–0.69) 1.37 (0.94–2.00) 1.33 (0.76–2.33)
2. (0.63–0.65) 1.64 (1.13–2.36) 1.30 (0.73–2.30)
1. (0.49–0.62) 1.93 (1.35–2.77) 1.80 (1.05–3.08)
Data are ORs (95% CI) adjusted for age, sex, and follow-up time.
TABLE 3
ORs of incident impaired fasting glucose or incident diabetes per






Arteriolar narrowing* 1.12 (0.98–1.27) 1.08 (0.89–1.31)
Venular dilatation† 1.13 (1.00–1.29) 1.09 (0.90–1.33)
AVR‡ 1.29 (1.13–1.46) 1.19 (0.98–1.45)
Data are ORs (95% CI) adjusted for age, sex, and follow-up time. *Per
SD decrease in arteriolar diameter. †Per SD increase in venular
diameter. ‡Per SD decrease in AVR.
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patients (20), thought to result from retinal hypoxia and
lactate accumulation (20,21). Successful treatment of pro-
liferative diabetic retinopathy with retinal photocoagula-
tion has been shown to be accompanied by a reduction in
venular diameters, possibly due to less retinal hypoxia
(21). In normoglycemic individuals, it has been observed
that administration of intravenous dextrose resulted in
retinal venular dilatation (7). In a case-control study, 266
patients with juvenile diabetes had significantly larger
venular diameters (396.5 m) compared with 129 control
subjects (368.0 m) (8). Also, in a population-based cohort
study on 996 diabetic patients, larger venular diameters
were associated with 4 years’ progression of retinopathy
(relative risk 4th vs. 1st quartile: 2.3 [95% CI 1.4–4.0]) and
with 14-year incidence of proliferative retinopathy (4.3
[1.5–12.2]) (21). Venular and to a lesser extent arteriolar
dilatation has also been described in other vascular beds,
including the renal and cerebral circulation (22). However,
the actual mechanisms underlying venular dilatation re-
main unclear.
An important limitation is the use of different methods
to diagnose diabetes at baseline and follow-up. Because of
its inconvenience to patients, the oral glucose tolerance
test was not performed at the follow-up examination.
Instead, it was decided to use glucose levels after over-
night fast. It has been reported that diagnosing diabetes
with fasting glucose levels would result in fewer cases
than with oral glucose tolerance test, especially in the
elderly (23,24). Some participants thus would have ob-
tained a diagnosis of diabetes had an oral glucose toler-
ance test been performed at follow-up. They might
currently have been misclassified as nondiabetic based on
their fasting levels. Because retinal vessel measurements
and diagnosis of diabetes were assessed independently
from each other, this misclassification would have been
random, resulting in broader CIs and underestimation of
the associations.
Another potential limitation of our study is the number
of nonparticipants at baseline. As we described previously,
there were only small differences in baseline cardiovascu-
lar risk factors between individuals with and without
gradable transparencies (11). Furthermore, individuals
who had an oral glucose tolerance test were hardly
different from those without these data with respect to
their cardiovascular risk profile (data not shown). These
comparisons suggest that selection bias, if any, played a
limited role at baseline.
There are several explanations for the fact that the
associations were stronger and more significant for im-
paired fasting glucose than for diabetes. We had three
times more cases with impaired fasting glucose than with
diabetes. There might be an under representation of
diabetic cases in our study population, because nonpartic-
ipants at follow-up were significantly older, had higher
blood pressures, were more often smokers, and had more
carotid artery plaques. As these risk factors also increase
the risk of diabetes, the nonparticipants would have more
often developed diabetes. Furthermore, those who died
during follow-up had an even worse cardiovascular risk
profile, including significantly larger venular diameters
after adjustment for age and sex. Because those who
develop diabetes are more likely to die than those who
have normal glucose, it is possible that there is selective
nonparticipation of people who had larger venular diame-
ters and developed diabetes.
The difference in associations for impaired fasting glu-
cose and diabetes might also be explained by the de-
creased capacity of the vessels to dilate at baseline in
participants who developed diabetes due to higher age or
blood pressures compared with those who developed
impaired fasting glucose. In our population, both mean age
and blood pressure at baseline were not significantly
different between the two groups. What we did find,
however, is that although all participants had a normal
oral glucose tolerance test at baseline, subjects who
developed incident diabetes (6.21 mmol/l) already had a
significantly higher postload glucose level at baseline than
those who developed impaired fasting glucose (5.98 mmol/
l). A higher glucose level could result in an accelerated
formation of advanced glycation end products, which can
accumulate in various vascular beds including the retinal
one leading to vascular wall stiffness and decreased endo-
thelium-dependent vasodilatation (25).
Prospective data from the Atherosclerosis Risk in Com-
munities Study showed that each SD decrease in the AVR
was related to a 26% increased risk of diabetes (6). Other
retinal arteriolar abnormalities such as arteriovenous nick-
ing (OR 0.94 [95% CI 0.65–1.35]) and focal arteriolar
narrowing (1.12 [0.78–1.59]) were not related to diabetes
(6). Based on these data, the authors concluded that
generalized arteriolar narrowing may play a role in its
development (6). More recently, their conclusion was
further supported by data from the Beaver Dam Eye Study
showing that smaller arteriolar diameters increased the
TABLE 4
Multivariable adjusted ORs of incident impaired fasting glucose







Arteriolar narrowing* 0.99 (0.86–1.15) 1.02 (0.82–1.27)
Venular dilatation† 1.15 (0.99–1.34) 1.08 (0.86–1.36)
AVR‡ 1.14 (0.98–1.32) 1.09 (0.87–1.36)
Data are ORs (95% CI) adjusted for age, sex, follow-up time, diastolic
and systolic blood pressure, smoking, BMI, serum total and HDL
cholesterol, C-reactive protein, and carotid artery plaque score. *Per
SD decrease in arteriolar diameter. †Per SD increase in venular
diameter. ‡Per SD decrease in AVR.
TABLE 5
Multivariable adjusted ORs of incident impaired fasting glucose
or incident diabetes per SD difference in baseline retinal vessel






Age 70 years 231 88
Arteriolar narrowing* 1.00(0.85–1.19) 0.98(0.76–1.28)
Venular dilatation† 1.23(1.02–1.47) 1.18(0.89–1.56)
AVR‡ 1.21(1.01–1.45) 1.13(0.86–1.47)
Age 70 years 74 30
Arteriolar narrowing* 0.93(0.68–1.26) 1.08(0.71–1.65)
Venular dilatation† 1.02(0.76–1.37) 0.91(0.60–1.37)
AVR‡ 0.95(0.70–1.29) 1.00(0.67–1.49)
Data are n or ORs (95% CI) adjusted for age, sex, follow-up time,
diastolic and systolic blood pressure, smoking, BMI, serum total and
HDL cholesterol, C-reactive protein, and carotid artery plaque score.
*Per SD decrease in arteriolar diameter. †Per SD increase in venular
diameter. ‡Per SD decrease in AVR.
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risk of diabetes (OR per SD decrease in arteriolar diame-
ters: 1.11 [95% CI 1.00–1.23]) (26). In the present study, we
confirmed these findings with respect to the AVR. Our data
showed that the associations with smaller arteriolar diam-
eters disappeared after additional adjustments, pointing
toward the involvement of inflammation and atherosclero-
sis in the pathogenesis of diabetes. We did not have
information on other retinal arteriolar signs (focal arterio-
lar narrowing or arteriovenous nicking). With respect to
venular diameters, we have previously shown that larger
diameters were related to markers of atherosclerosis,
higher levels of inflammation, and smoking (11). Because
these factors also give an increased risk of diabetes, these
factors could underlie the associations we have described.
Although nonsignificant, the associations with venular
dilatation remained unaltered after adjustment for these
factors (Table 4). Taken together, both changes in venular
and arteriolar diameters may be involved in the pathogen-
esis of diabetes.
Given that the Atherosclerosis Risk in Communities
Study, which found stronger associations between AVR
and diabetes (6), studied younger people, we decided to
stratify on age. Our data also revealed that these associa-
tions were mainly present in the younger participants. In
the older participants, venular dilatation was not related to
impaired fasting glucose or diabetes probably due to
decreased vasodilatory capacity in these individuals.
In conclusion, in our study the association of AVR with
impaired fasting glucose and diabetes seemed to be largely
explained by venular dilatation. These data support the
view that venular changes are present already in the early
stages of diabetes. In a clinical setting, venular changes
such as dilatation could be assessed using a (semi) auto-
mated system to explore the full extent of microvascular
abnormalities in diabetes. Further research needs to be
conducted to elucidate the actual mechanisms that lead to
these alterations.
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